, the Third Circuit issued an opinion in Mylan v. Warner Chilcott, upholding the Eastern District of Pennsylvania's holding on summary judgement that Defendants product hopping conduct did not violate the Sherman Act. Product hopping generally ... JD Supra, 2 weeks ago
Doryx: Third Circuit Affirms Dismissal of Product Hopping Claim - JD Supra, 3 weeks ago
1 images for "warner chilcott"
Merck Sharp & Dohme B.V. v. Warner Chilcott Company, LLC, et al., C.A. No. 13-2088 GMS, August 26, 2016. Sleet, J. Court issues post-trial rulings regarding validity of the patent-in-suit and Rule 52(c) motions. The disputed technology relates to ...JD Supra, 1 month ago
New Valeant CEO Joseph Papa has filled another link in the drugmaker's executive ranks as he tries to forge a chain of command that is strong enough to lift the company out of the financial and legal quag in which it is mired. Valeant today said ...FiercePharma, 2 months ago Valeant's New CFO Is An Excellent Hire Seeking Alpha, 2 months ago New CFO Tops Off Shake-Up At Valeant -- WSJ Nasdaq, 2 months ago Valeant Names Herendeen From Zoetis as CFO to Replace Rosiello La Repubblica, 2 months ago
By Dana A. Elfin Oct. 20 — The FTC is urging a federal appeals court to rehear Mylan Pharmaceuticals Inc.'s case alleging other drugmakers tried to monopolize the market for the branded antibiotic Doryx Mylan Pharm., Inc. v. Warner Chilcott ...Bloomberg BNA, 2 days ago
Human Reproductive Technologies Market to Reach US$27.1 bn by 2019; Lifestyle Changes Linked to Growing Infertility
A recent report on the global human reproductive technologies market has been published by Transparency Market Research. The report, titled Human Reproductive Technologies Market - Global Industry Analysis, Size, Procedures, Growth, Trends and ...MyNewsDesk, 2 days ago Contraceptives Market Would Reach $43,812 Million by 2022, Globally - Allied Market Research TickerTech.com, 2 weeks ago
Howard Root, CEO, Vascular Solutions Howard Root is one ticked-off medtech CEO. The head of Vascular Solutions in Maple Grove, Minneapolis, and his company were found not guilty in February on 10 criminal counts alleging off-label use of a ...MedCity News, 2 days ago
Latest industry research report on: Global Contraceptives Market 2016: Industry Research, Size, Shares, Key Trends, Demand, Growth to 2022 Contraception is a method which prevents pregnancy using drugs or a device. Contraception is also known as ...MyNewsDesk, 1 week ago Contraceptives Market 2016: Contraceptive drugs, Contraceptive devices, Sponges Before It's News, 1 month ago
Form 3 - Initial statement of beneficial ownership of securities SEC Accession No. 0001140361-16-082327 Filing Date 2016-10-07 2016-10-07 20:00:15 Period of Report 2016-10-07 Filing Date Changed 2016-10-07 Document Format Files ...SEC Filings, 2 weeks ago 3 - Avista Acquisition Corp. (0001661187) (Reporting) SEC Filings, 2 weeks ago 3 - Avista Healthcare Public Acquisition Corp. (0001661181) (Issuer) SEC Filings, 2 weeks ago
Form 3 - Initial statement of beneficial ownership of securities SEC Accession No. 0001140361-16-082327 Filing Date 2016-10-07 2016-10-07 20:00:15 Period of Report 2016-10-07 Filing Date Changed 2016-10-07 Document Format Files ...SEC Filings, 2 weeks ago 3 - Burgstahler David F (0001374179) (Reporting) SEC Filings, 2 weeks ago
Hospira, Inc. et al.; Withdrawal of Approval of 44 New Drug Applications and 158 Abbreviated New Drug Applications
NDA 005264 Heparin Sodium Injection Hospira, Inc., 275 North Field Dr., Bldg. H2-2, Lake Forest, IL 60045-5046. NDA 009470 Xylocaine Viscous (lidocaine hydrochloride (HCl)) Solution Fresenius Kabi USA LLC, Three Corporate Dr., Lake Zurich, IL ...Federal Register, 2 weeks ago
on your WebpageAdd Widget >Get your members hooked!